Paper · 25972002
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
Sun LL and 25 others. Sci Transl Med, 2015. Cited by 234 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Papers, record 25972002. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25972002
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Bispecific | Major topic |
| Antigens, CD20 | Major topic |
| CD3 Complex | Major topic |
| Leukemia, B-Cell | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Humans | |
| Macaca fascicularis | |
| Mice | |
| Mice, Transgenic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA081554 | NCI NIH HHS | United States | R01CA081554 | PubMed and NIH |
Source NIH RePORTER
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by163
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 234 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,922,970 | PTPN2/PTPN1 inhibition enhances ex vivo T- cell responses and potentiates mosunetuzumab activity in chronic lymphocytic leukemia. | Front Immunol | 2026 | https://conductscience.org/library/papers/42922970 | PubMed |
| 42,819,571 | Chemoimmunotherapy-associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20-directed cellular therapies. | Hemasphere | 2026 | https://conductscience.org/library/papers/42819571 | PubMed |
| 42,541,087 | Fixed Treatment Duration Mosunetuzumab in Patients With Relapsed or Refractory Follicular Lymphoma: Perspectives From US Advanced Practice Providers. | J Adv Pract Oncol | 2026 | https://conductscience.org/library/papers/42541087 | PubMed |
| 42,385,177 | Bispecific Antibody-Based Combination Therapies for B-Cell Lymphomas: Current Evidence and Future Perspectives. | Int J Cancer | 2026 | https://conductscience.org/library/papers/42385177 | PubMed |
| 42,355,593 | Precision Medicine in Non-Hodgkin Lymphoma: Advances in BTK Inhibition, CD30-Directed Antibody-Drug Conjugates, and HDAC-Mediated Epigenetic Therapy with Pirtobrutinib, Brentuximab Vedotin, and Belinostat. | J Clin Med | 2026 | https://conductscience.org/library/papers/42355593 | PubMed |
| 42,309,556 | Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus. | Lupus Sci Med | 2026 | https://conductscience.org/library/papers/42309556 | PubMed |
| 42,298,056 | Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42298056 | PubMed |
| 42,283,231 | A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B-Cell Lymphoma. | Am J Hematol | 2026 | https://conductscience.org/library/papers/42283231 | PubMed |
| 42,178,273 | Mosunetuzumab for relapsed follicular lymphoma presenting with chylothorax: A case report and literature review. | J Clin Exp Hematop | 2026 | https://conductscience.org/library/papers/42178273 | PubMed |
| 42,041,388 | Development of Bispecific Antibody Targeting Human IL-17A and IL-6. | Antibodies (Basel) | 2026 | https://conductscience.org/library/papers/42041388 | PubMed |
1 to 10 of 163
See all 163 cited byGenes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD19 | 930 | PubTator's text mining | https://conductscience.org/library/genes/930 | NCBI Gene |
| KRT20 | 54,474 | PubTator's text mining | https://conductscience.org/library/genes/54474 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25972002
GET https://conductscience.org/api/papers/v1/25972002/authors?page=2